NBIX Neurocrine Biosciences, Inc.
Healthcare$155.73-0.62%ClosedMarket Cap: $15.66B
As of 2026-05-26
Analyst Consensus
Consensus
Buy
Target (Consensus)
$184.38
Target (Median)
$185.00
Target Range
$140.00 - $230.00
Upside from current price: 18.4%
Rating Distribution
4 Strong Buy20 Buy4 Hold0 Sell0 Strong Sell
Recent Analyst Ratings
| Date | Firm | Action | Rating | Previous |
|---|---|---|---|---|
| 2026-05-08 | JP Morgan | maintain | Overweight | Overweight |
| 2026-05-07 | Truist Securities | maintain | Buy | Buy |
| 2026-05-06 | Guggenheim | maintain | Buy | Buy |
| 2026-05-06 | Piper Sandler | maintain | Overweight | Overweight |
| 2026-05-06 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| 2026-05-06 | Citigroup | maintain | Buy | Buy |
| 2026-05-06 | RBC Capital | maintain | Outperform | Outperform |
| 2026-05-06 | Wedbush | maintain | Outperform | Outperform |
| 2026-04-22 | Leerink Partners | maintain | Outperform | Outperform |
| 2026-04-07 | Canaccord Genuity | maintain | Buy | Buy |
Forward Estimates
| Period | EPS Est. | Revenue Est. | # Analysts |
|---|---|---|---|
| Fri Dec 31 | $9.47 | $4.29B | 11 |
| Sun Dec 31 | $11.80 | $4.81B | 14 |
| Mon Dec 31 | $13.41 | $5.08B | 8 |
| Tue Dec 31 | $14.88 | $5.43B | 12 |